BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 16501588)

  • 1. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
    Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD.
    Kim DH; Sohn SK; Baek JH; Lee KH; Lee JH; Choi SJ; Shin IH
    Bone Marrow Transplant; 2007 Oct; 40(8):779-84. PubMed ID: 17700602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
    Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
    Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
    Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation.
    Kim DH; Sohn SK; Kim JG; Suh JS; Lee KS; Lee KB
    Bone Marrow Transplant; 2004 May; 33(10):1025-30. PubMed ID: 15064689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset.
    Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Ahn JS; Kim YK; Yang DH; Lee JJ; Kim HJ; Choi YJ; Shin HJ; Chung JS; Cho GJ; Sohn SK
    Bone Marrow Transplant; 2010 Oct; 45(10):1540-5. PubMed ID: 20190848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
    Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation.
    Mlynarczewska A; Wysoczanska B; Karabon L; Bogunia-Kubik K; Lange A
    Bone Marrow Transplant; 2004 Aug; 34(4):339-44. PubMed ID: 15235581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD.
    Rajasekar R; Mathews V; Lakshmi KM; Sellathamby S; George B; Viswabandya A; Daniel D; Chandy M; Srivastava A
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):344-50. PubMed ID: 18275901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
    Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Mohty M; Bagattini S; Chabannon C; Faucher C; Bardou VJ; Bilger K; Vey N; Gaugler B; Stoppa AM; Coso D; Ladaique P; Olive D; Viens P; Blaise D
    Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
    Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
    Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
    Min CK; Kim SY; Lee MJ; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Cho CS
    Bone Marrow Transplant; 2006 Jul; 38(2):149-56. PubMed ID: 16751784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
    Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.